Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.
This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.
Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.
Nevro Corp. (NYSE: NVRO) reported its Q4 and full-year 2024 financial results, highlighting a pending acquisition by Globus Medical for $250 million ($5.85 per share) expected to close in Q2 2025. The company's Q4 2024 worldwide revenue decreased 9.1% to $105.5 million, with U.S. revenue declining 9.9% to $91.4 million.
Key Q4 metrics include: gross profit of $65.9 million (62.5% margin), net loss from operations of $51.4 million, and adjusted EBITDA of negative $5.2 million. For full-year 2024, worldwide revenue decreased 3.9% to $408.5 million, with gross profit at $269.5 million (66.0% margin).
Notable developments include the launch of HFX iQ™ with HFX AdaptivAI™ platform in November 2024 and its European expansion in January 2025. The company's cash position strengthened to $292.5 million as of December 31, 2024.
Nevro Corp. (NYSE: NVRO), a medical device company focused on chronic pain treatment solutions, has announced the granting of inducement restricted stock unit awards to 10 new non-executive employees. The awards, approved by the Compensation Committee on January 7, 2025, cover 21,026 shares of Nevro's common stock.
The grants were made under the Nevro Corp. 2023 Inducement Award Plan and will vest over a three-year period, contingent upon continued employment. These awards were granted as material inducements to employment in compliance with NYSE Listed Company Manual Rule 303A.08.
Nevro Corp. (NYSE: NVRO) has released preliminary, unaudited financial results for Q4 and full-year 2024. The company expects Q4 2024 worldwide revenue of $105-106 million, showing a 9-10% decrease compared to Q4 2023. Full-year 2024 worldwide revenue is anticipated at $408-409 million, representing a 4% year-over-year decrease.
Despite the decline, the full-year revenue exceeded previous guidance, primarily due to higher-than-expected spinal cord stimulation device replacement procedures in Q4. The company's cash position strengthened, with cash, cash equivalents, and short-term investments reaching approximately $292.5 million as of December 31, 2024, marking a $15.5 million increase from September 30, 2024.
Nevro continues to invest in direct-to-consumer advertising, expecting benefits to materialize throughout 2025, particularly in the second half. The company remains in ongoing discussions exploring strategic options to accelerate growth and enhance shareholder value.
Nevro Corp. (NYSE: NVRO) has announced the granting of inducement restricted stock unit awards to 20 new non-executive employees. The awards, approved by the Compensation Committee on December 7, 2024, cover 26,000 shares of Nevro's common stock. These grants were made under the Nevro Corp. 2023 Inducement Award Plan and will vest over a three-year period, contingent on continued employment. The awards were granted in accordance with NYSE Listed Company Manual Rule 303A.08 as material inducements to employment.
Nevro Corp. (NYSE: NVRO) has published new data demonstrating the advantages of its Nevro1™ SI Joint Fusion System compared to other approaches. The study, published in Medical Devices: Evidence and Research, shows that Nevro1, a posterior integrated transfixation cage system, offers enhanced stability, minimized bone removal, and increased fusion potential versus posterolateral cylindrical threaded single-implant systems. The research revealed that Nevro1 and lateral triangular rods produced equivalent motion reduction, while providing the most surface area for fusion, enabling better SI joint arthrodesis opportunities.
Nevro Corp. (NYSE: NVRO) has granted inducement restricted stock unit awards to 24 new non-executive employees. The awards, covering 37,726 shares of Nevro's common stock, were granted on November 7, 2024, under the company's 2023 Inducement Award Plan. These grants, approved by the Compensation Committee of Nevro's Board of Directors, will vest over a three-year period, contingent on continued employment. The awards were issued in accordance with NYSE Listed Company Manual Rule 303A.08 as material inducements to employment.
Nevro Corp. (NYSE: NVRO) has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system, enabling marketing in all CE-recognizing countries. HFX iQ is the first SCS system with AI technology combining high-frequency therapy with cloud data insights for personalized pain relief. The system features indication-specific algorithms, customized therapy adjustments through the HFX App, and the only 10 kHz Therapy with CE-marked labeling for all major SCS indications. Market launch in select European countries is planned for Q1 2025. The system previously received FDA approval in 2022.
Nevro Corp. (NYSE: NVRO) reported Q3 2024 financial results with worldwide revenue of $96.9 million, down 6.7% year-over-year. U.S. revenue decreased 6.5% to $83.9 million, while international revenue fell 7.7% to $13.0 million. The company reported a net loss from operations of $13.9 million and negative adjusted EBITDA of $1.8 million. Despite challenges, Nevro maintained its full-year 2024 revenue guidance of $400-405 million and raised its adjusted EBITDA guidance to negative $18-16 million. The company announced the release of HFX AdaptivAI and received regulatory approval for HFX iQ in Europe.
Nevro Corp. (NYSE: NVRO) published new data showing significant improvements in patients with painful diabetic neuropathy (PDN) and Type 2 diabetes using their 10 kHz high-frequency spinal cord stimulation therapy. The 24-month study of 144 patients demonstrated a 79.8% mean pain reduction and notable improvements in multiple health metrics. Patients with high HbA1c levels achieved reductions of up to 1.1%, while those with higher BMI experienced weight loss up to 5.4 kg. The study also showed a 65.2% improvement in sleep quality, marking the first SCS study to demonstrate long-term, significant reductions in HbA1c and weight for PDN patients.
Nevro Corp. (NYSE: NVRO), a global medical device company specializing in chronic pain treatment solutions, has announced new employee inducement grants. On October 7, 2024, the company's Compensation Committee granted restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees. These awards, granted under the Nevro Corp. 2023 Inducement Award Plan, are designed to induce the recipients to accept employment with Nevro.
The awards vest over a three-year period, contingent on continued employment with Nevro through each vesting date. These grants were made in accordance with the NYSE Listed Company Manual Rule 303A.08 as material inducements to employment. Nevro also encourages investors to regularly check their website's 'Investor Relations' section for important company information.
